This study randomized 1: 1 patient who had been hospitalized for acute coronary syndrome within 30 days after entry to darapladib versus placebo study. A total of 6504 patients were included in the darapladib group and 6522 in the placebo group. At a mean of 2.5 years follow-up a combined cardiovascular events rate was observed, 16.3% for darapladib group versus 15.6% in the placebo group (n = 0.93). No significant differences were observed when considering cardiovascular death or myocardial infarction separately.
Conclusion
Darapladib, a direct inhibitor of phosphodiesterase A2 showed no benefit over placebo in patients at high risk of a new acute coronary syndrome.
Michelle O’Donoghue
2014-08-31
Original title: The Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial: Primary Results.
